New Antiviral Evidence Supports Early Testing, Targeted Treatment & Better Sampling to Reduce Impact of Flu on Healthcare Systems
New antiviral evidence revealed baloxavir (Xofluza) as the superior flu treatment to oseltamivir (Tamiflu), and this emerging antiviral treatment strategy amplifies the consequences of delayed diagnoses. What does this mean for patients and healthcare systems, and how does smarter nasal sampling play a larger role than once thought?











